Imbruvica Approval Expanded to Include Graft Versus Host Disease

WEDNESDAY, Aug. 2, 2017 — The U.S. Food and Drug Administration on Wednesday expanded approval for the anti-cancer drug Imbruvica (ibrutinib) to include adults with chronic graft versus host disease (cGVHD).
cGVHD is a deadly condition that affects…
Source: Topamax